---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006794"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:25:53.989004+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q3 revenue $25.4M (-6% YoY); adjusted EBITDA margin 8.9%

## Summary
- Q3 2023 revenues $25.4M vs $26.9M prior year; gross margin improved to 58.1% from 45.2%.
- GAAP net loss $1.2M ($0.03/share); adjusted EPS $0.01; adjusted EBITDA $2.2M (8.9% margin).
- Operating cash flow $4.4M; debt reduced $2.8M in Q3, total debt $38.7M.
- Updated FY2023 guidance: revenue approx flat YoY, gross margin ~60%, adjusted EBITDA margin 13%-14%.
- Asia headwinds and $1.3M revenue impact from discontinued products; North America revenue grew.

## SEC filing metadata
- accession: 0001171843-23-006794
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/f8k_110323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006794
- JSON: https://secwatch.observer/filing/0001171843-23-006794.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006794.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported the third quarter ended September 30, 2023 results: revenue $25.4 million, net income ($1.2) million, EPS $(0.03).
  - Period: the third quarter ended September 30, 2023
  - Revenue: $25.4 million
  - Net income: ($1.2) million
  - EPS: $(0.03)
  - Result: reported results
  source text: a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2023 Financial Results · Q3 Revenues of $25.4 million · Q3 Gross Margin of 58.1% · Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million · Continued strong operating cash flow drove debt reduction of $8.3
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm
- Earnings Releases
  HARVARD BIOSCIENCE INC updated its fiscal 2023 guidance (reaffirmed).
  - Period: fiscal 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: we now expect our fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5 percentage point headwind from discontinued products. For the year 2023, we continue to expect gross margins of approximately 60%. We now expect adjusted EBITDA margins in the 13% to 14% range.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm
- Earnings Releases
  HARVARD BIOSCIENCE INC reported the nine months ended September 30, 2023 results: revenue $84.1 million, net income ($1.6) million, EPS $(0.04).
  - Period: the nine months ended September 30, 2023
  - Revenue: $84.1 million
  - Net income: ($1.6) million
  - EPS: $(0.04)
  - Result: reported results
  source text: debt was reduced by $3.8 million during the third quarter of 2023. Nine Months ended September 30, 2023 Highlights For the nine months ended September 30, 2023, revenues were $84.1 million, compared to $84.9 million in the same period a year ago. Revenues for the nine months ended September 30, 2023 include a net reduction of $4.1 million from discontinued products
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.